サクビトリル・バルサルタン
参考資料

1 2 3  “Entresto 24/26 tablets, Entresto 49/51 tablets, Entresto 97/103 tablets (sacubitril/valsartan) Product Information”. Therapeutic Goods Administration (TGA).   Novartis. 21 September 2020閲覧。
↑  “Sacubitril / valsartan (Entresto) Use During Pregnancy”. Drugs.com (20 November 2019). 21 September 2020閲覧。
↑  “Entresto 24 mg/26 mg film-coated tablets - Summary of Product Characteristics (SmPC)”. (emc). 21 September 2020閲覧。
1 2 3  “Entresto- sacubitril and valsartan tablet, film coated”. DailyMed (14 June 2020). 21 September 2020閲覧。
1 2 3  “Entresto EPAR”. European Medicines Agency (EMA). 21 September 2020閲覧。
↑  “Neparvis EPAR”. European Medicines Agency (EMA). 23 September 2020閲覧。
↑  “KEGG DRUG: サクビトリルバルサルタンナトリウム水和物”. www.kegg.jp. 2021年8月26日閲覧。
1 2 3  “Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition”. Circulation 133 (11):  1115–24. (March 2016). doi:10.1161/CIRCULATIONAHA.115.018622. PMC 4800749. PMID 26976916. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4800749/.
1 2 3  “2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America”. Circulation 134 (13):  e282–93. (27 September 2016). doi:10.1161/CIR.0000000000000435. PMID 27208050.
1 2 3  "FDA approves new drug to treat heart failure" (Press release). U.S. Food and Drug Administration (FDA). 7 July 2015. 2018年1月26日時点のオリジナルよりアーカイブ。
↑  “Entresto (sacubitril/valsartan) Tablets”. U.S. Food and Drug Administration (FDA) (14 August 2015). 21 September 2020閲覧。
1 2  “サクビトリルバルサルタンが製造販売承認を取得／ノバルティス ファーマ｜CareNet.com”. CareNet.com. 2021年8月26日閲覧。
1 2 3  “エンレスト錠50mg／エンレスト錠100mg／エンレスト錠200mg 添付文書”. www.info.pmda.go.jp.   PMDA. 2021年10月22日閲覧。
↑  “Recovery of left ventricular dysfunction after sacubitril/valsartan: predictors and management”. J Cardiol 75 (3):  233–241. (September 2019). doi:10.1016/j.jjcc.2019.08.005. PMID 31563433.
1 2 3 4  McMurray, John J.V. et al. (30 August 2014). “Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure”. N Engl J Med 371 (11):  993–1004. doi:10.1056/NEJMoa1409077. hdl:2336/552372. PMID 25176015. http://orbilu.uni.lu/handle/10993/27659.
1 2 3 4 5 6 7  “Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction”. New England Journal of Medicine 381 (17):  1609–1620. (October 2019). doi:10.1056/NEJMoa1908655. ISSN 0028-4793. PMID 31475794. http://eprints.gla.ac.uk/195500/1/195500.pdf.
↑  Martin N, Manoharan K, Thomas J, Davies C, Lumbers RT. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction. Cochrane Database of Systematic Reviews 2018, Issue 6. Art. No.: CD012721. DOI: 10.1002/14651858.CD012721.pub2. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012721.pub2/epdf/full
1 2 3 4 5 6 7 8  “Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure”. New England Journal of Medicine 371 (11):  993–1004. (September 2014). doi:10.1056/NEJMoa1409077. hdl:2336/552372. ISSN 0028-4793. PMID 25176015. http://www.hirsla.lsh.is/lsh/handle/2336/552372.
1 2 3 4 5  “Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure”. New England Journal of Medicine 380 (6):  539–548. (February 2019). doi:10.1056/NEJMoa1812851. ISSN 0028-4793. PMID 30415601.
↑  Mutschler, Ernst; Schäfer-Korting, Monika (2001) (ドイツ語). Arzneimittelwirkungen (8 ed.). Stuttgart: Wissenschaftliche Verlagsgesellschaft. p. 579. ISBN 978-3-8047-1763-3
↑  “Heart Failure with Preserved Ejection Fraction”. J. Cardiovasc. Pharmacol. 62 (1):  13–21. (2013). doi:10.1097/FJC.0b013e31829a4e61. PMC 3724214. PMID 23714774. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3724214/.
↑  Solomon, SD. “HFpEF in the Future: New Diagnostic Techniques and Treatments in the Pipeline”. p. 48. 26 January 2012閲覧。
↑  “Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi)”. J Clin Pharmacol 50 (4):  401–14. (2010). doi:10.1177/0091270009343932. PMID 19934029.
↑  Schubert-Zsilavecz, M; Wurglics, M. “Neue Arzneimittel 2010/2011” (ドイツ語)
↑  “Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension”. Journal of Hypertension 10 (7):  607–13. (July 1992). doi:10.1097/00004872-199207000-00002. PMID 1321186.
1 2  “Chronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin II”. Journal of Hypertension 11 (4):  407–16. (April 1993). doi:10.1097/00004872-199304000-00011. PMID 8390508.
1 2  “Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial”. American Journal of Hypertension 17 (2):  103–11. (February 2004). doi:10.1016/j.amjhyper.2003.09.014. PMID 14751650.
↑  “Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure”. The New England Journal of Medicine 380 (6):  539–48. (February 2019). doi:10.1056/NEJMoa1812851. PMID 30415601.
↑  “Is Entresto good for the brain?”. World J Cardiol 9 (7):  594–599. (2017). doi:10.4330/wjc.v9.i7.594. PMC 5545143. PMID 28824789. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5545143/.
↑  “New drug therapies interfering with the renin-angiotensin-aldosterone system for resistant hypertension”. J Renin Angiotensin Aldosterone Syst 14 (4):  285–9. (2013). doi:10.1177/1470320313513408. PMID 24222656.
1 2  Lili Feng, L (2012). “LCZ696: a dual-acting sodium supramolecular complex”. Tetrahedron Letters 53 (3):  275–276. doi:10.1016/j.tetlet.2011.11.029.
↑  “CardioMEMS HF System (St. Jude Medical, Inc.) and Sacubitril/Valsartan (Entresto, Novartis AG) for management of congestive heart failure: effectiveness, value, and value-based price benchmarks : final report”. (1 December 2015). 101672986. http://resource.nlm.nih.gov/101672986
↑  Richard Lehman's journal review—8 September 2014. NEJM 4 Sep 2014. Vol 371. The BMJ, 8 September 2014.
↑  Roger Sergel for Medpage Today.  5 Game-Changers in Cardiology in 2015: Entresto
↑  “Dual Angiotensin Receptor and Neprilysin Inhibition with Sacubitril/Valsartan in Chronic Systolic Heart Failure: Understanding the New PARADIGM”. Ann Pharmacother 49 (11):  1237–51. (2015). doi:10.1177/1060028015593093. PMID 26175499.
↑  “Role of neprilysin inhibitor combinations in hypertension: insights from hypertension and heart failure trials”. Eur. Heart J. 36 (30):  1967–73. (2015). doi:10.1093/eurheartj/ehv142. PMID 25898846. http://doc.rero.ch/record/299366/files/ehv142.pdf.
↑  Husten, Larry (31 March 2014). “Novartis Trial Was Stopped Early Because Of A Significant Drop In Cardiovascular Mortality”. Forbes. https://www.forbes.com/sites/larryhusten/2014/03/31/novartis-trial-was-stopped-early-because-of-a-significant-drop-in-cardiovascular-mortality/#2226cab84010
1 2  “Neprilysin Inhibition in Heart Failure with Reduced Ejection Fraction: A Clinical Review”. Pharmacotherapy 35 (9):  823–37. (2015). doi:10.1002/phar.1629. PMID 26406774.
↑  “Sacubitril/Valsartan Combination Drug: 2 Years Later”.   American College of Cardiology (3 March 2017). 2021年8月26日閲覧。
↑  “Angiotensin Receptor-Neprilysin Inhibition”. J. Cardiovasc. Pharmacol. Ther. 22 (4):  356–364. (July 2017). doi:10.1177/1074248416683049. ISSN 1074-2484. PMID 28587583.
↑  “Patients Not Meeting PARADIGM-HF Enrollment Criteria Are Eligible for Sacubitril/Valsartan on the Basis of FDA Approval: The Need to Close the Gap”. JACC Heart Fail 5 (6):  460–463. (June 2017). doi:10.1016/j.jchf.2017.03.007. PMID 28571599.
↑  “Richard Lehman's journal review—8 September 2014”. The BMJ (8 September 2014). 20 May 2019閲覧。
↑  “Do limitations in the design of PARADIGM-HF justify the slow real world uptake of sacubitril/valsartan (Entresto)?”. Cardiovascular Drugs and Therapy 32 (6):  633–5. (2018). doi:10.1007/s10557-018-6830-x. PMID 30232657. https://static1.squarespace.com/static/55550f38e4b0884d8d80118e/t/5bd915c4032be422670e74ef/1540953541892/2018.+Do+Limitations+in+the+desing+of+PARADIGM-HF+justify+the+slow+real+world+uptake+of+SacubitrilValsartan+Entresto.pdf.